EyePoint's EYP-1901 Tipped to Transform Wet AMD Market, Analyst Predicts Potential $870M Sales by 2035

JonesResearch has initiated coverage of ophthalmic biopharmaceutical company EyePoint Pharmaceuticals Inc EYPT with a Buy rating and a $26 price target

The analyst writes that EyePoint's lead asset EYP-1901 for age-related macular degeneration (AMD) represents a potential first-in-class maintenance therapy utilizing the company's Durasert technology, which enables consistent and highly targeted drug release through 6 months or longer from a single intravitreal injection. 

The company is conducting its Phase 2 DAVIO 2 trial of EYP-1901 in previously treated wet AMD patients and expects to report top-line results from the trial in December 2023. 

Also Read: EyePoint Pharma Offloads Its Commercially-Available Eye Implant For $82.5M Plus Royalties.

JonesResearch is bullish on EYP-1901 based on its durability of vision-preserving effects shown to date, as well as its novel mechanism of action as a next-generation tyrosine kinase inhibitor.

It says wet AMD presents a potential multi-billion dollar opportunity for EYP-1901 as a 6-month maintenance therapy following induction with any standard-of-care anti-VEGF biologic.

Few therapies are currently available for wet AMD, including standard-of-care VEGF-A inhibitors Regeneron Pharmaceuticals Inc's REGN Eylea (aflibercept) and Roche Holding AG's RHHBY Lucentis (ranibizumab), as well as the more recently approved Vabysmo (faricimab), that collectively generated over $8 billion in global net sales in 2022.

The analyst estimates risk-adjusted US net sales of EYP-1901 to approach ~$870 million by 2035 with a 35% probability of success.

Looking beyond wet AMD, the company's follow-on programs in diabetic macular edema and non-proliferative diabetic retinopathy present additional blockbuster opportunities for EYP-1901, and a potentially meaningful upside to EYPT valuation.

Price Action: EYPT shares are up 7.68% at $7.15 on the last check Wednesday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: BiotechNewsHealth CareInitiationAnalyst RatingsMoversTrading IdeasGeneralBriefsExpert Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!